ACET

2.16012.20%
MJ

Michael J. Grissinger

Independent Director

Mr. Michael J. Grissinger, M.B.A. also known as Mike, is Director of Envisagenics, Inc. Mr. Grissinger, also known as Mike, M.B.A., is Independent Director of Lipocine Inc. from August 03, 2026 and Independent Director of Adicet Bio, Inc. (Nasdaq: ACET) from April 2025. He is Chairman of the Board of AnaCardio AB. He has decades of experience in the pharmaceutical industry, leading large value business development transactions across multiple therapeutic areas and products. Mr. Grissinger spent more than two decades at Johnson & Johnson where he served in a variety of senior level management roles, including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. At Johnson & Johnson, Mr. Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was also a member of the Immunology R&D/Commercial leadership team for Johnson & Johnson's Worldwide Immunology Franchise. Prior to Johnson & Johnson, Mr. Grissinger spent many years at Ciba-Geigy in finance, marketing and business development roles. Since his retirement in 2018, Mr. Grissinger has served on the boards of several public biotechnology companies. Mr. Grissinger is an experienced biotech company director serving on boards of public and private companies, including Board Chair roles. He serves on the boards of Akari Therapeutics and Aprea Therapeutics (Nasdaq: APRE), is Board Chair of Kira Biotech and serves on the board of directors of Envisagenics. He also advises several privately-held biotech companies. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University – Fox School of Business and Management in Philadelphia.

Positions